Crossmark

Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: initial results from the P-PRRT trial

Crossref DOI link: https://doi.org/10.1007/s00259-018-4209-7

Published Online: 2018-11-30

Published Print: 2019-03

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Del Prete, Michela

Buteau, François-Alexandre

Arsenault, Frédéric

Saighi, Nassim

Bouchard, Louis-Olivier

Beaulieu, Alexis

Beauregard, Jean-Mathieu http://orcid.org/0000-0003-2123-145X
Funding

Funding for this research was provided by:

Canadian Institutes of Health Research (MOP-142233)

Fonds de Recherche du Québec - Santé

Ministère de l'éducation et de l’enseignement supérieur du Québec
License Information

Text and Data Mining valid from 2018-11-30
More Information

Article History

Received: 24 July 2018

Accepted: 30 October 2018

First Online: 30 November 2018

Compliance with ethical standards

:

: None.

: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.